Oxiracetam is a recently synthesized nootropic that was tested as a
potential treatment for cognitive decline in patients with multi- infarct
dementia (MID) and primary degenerative dementia (PDD). Subjects were 34
MID patients and 39 PDD patients who met entrance criteria for the study. A
repeated measures ANOVA showed significant improvement in both patients
with MID and patients with PDD for word fluency. The total score on the
Relatives' Assessment of Global Symptomatology-Elderly showed significant
improvement for patients with PDD. The average score on the Instrumental
Activities of Daily Living Scale, however, showed a significant decline for
patients with PDD.
Abstract Teaser